Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The C-MORE study is prospective observational holistic longitudinal study which will characterise the prevalence of multi-organ injury among COVID-19 survivors post hospital discharge and assess its effects on quality of life, exercise tolerance and mental health.
Description: Characterise and compare the prevalence and extent of lung, heart, liver, kidney, brain injury on magnetic resonance imaging (MRI) in patients with moderate to severe COVID-19 disease with matched uninfected controls.
Measure: Prevalence of damage (quantitative measures of injury) on lung, heart, liver, kidneys and brain MRI. Time: 6 monthsDescription: Characterise and compare the prevalence and extent of lung, heart, liver and kidney, brain injury on magnetic resonance imaging (MRI) in patients with moderate to severe COVID-19 disease with matched uninfected controls.
Measure: Prevalence of damage (quantitative measures of injury) on lungs, heart, liver, kidneys and brain on MRI. Time: 3 and 12 monthsDescription: Characterise and compare the prevalence of cardiac, renal and liver injury on blood test in COVID-19 survivors and controls.
Measure: Prevalence of acute/chronic cardiac, renal and liver injury on blood tests. Time: 3, 6,12 monthsDescription: Characterise and compare VO2 max on cardiopulmonary exercise testing in COVID-19 survivors and controls.
Measure: VO2 max on cardiopulmonary exercise testing Time: 3, 6,12 monthsDescription: Characterise and compare the prevalence of lung function test abnormalities among survivors and controls.
Measure: Prevalence of abnormal lung function test (any of the following: Forced expiratory volume in 1 second (FEV1)< 80% of predicted FEV1, or forced vital capacity (FVC)<80% predicted, ratio of FEV1/FVC >0.7 or diffusion lung capacity (<80% predicted)) Time: 3, 6,12 monthsDescription: For each of the eight domains that the SF36 measures an aggregate percentage score is produced. The percentage scores range from 0% (lowest or worst possible level of functioning) to 100% (highest or best possible level of functioning).
Measure: Quality of life - Short form-36 SF-36 score Time: 3, 6,12 monthsDescription: Described and compare the prevalence of impaired cognition (MoCA) between COVID-19 survivors and controls. MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal.
Measure: Prevalence of impaired cognitive function on Montreal Cognitive assessment (MoCA<26) Time: 3, 6,12 monthsDescription: Compare 6-minute walk distance between COVID-19 survivors and controls.
Measure: 6-minute walk distance Time: 3, 6,12 monthsDescription: Compare prevalence and severity of anxiety between COVID-19 survivors and controls.
Measure: Severity of anxiety on GAD-7 (Score) Time: 3, 6,12 monthsDescription: Compare prevalence and severity of depression among COVID-19 survivors and controls. PHQ-9 total score for the nine items ranges from 0 to 27. Scores of 5, 10, 15, and 20 represent outpoints for mild, moderate, moderately severe and severe depression, respectively.
Measure: Severity of depression on PHQ-9 (Score) Time: 3, 6,12 monthsDescription: To assess the association of multi organ damage on MRI and inflammatory response.
Measure: Association between the extent of multi-organ injury (continuous variable) and markers of inflammation (white cell count). Time: 3,6,12 monthsDescription: To assess the association of ongoing symptomatology and multi-organ injury/inflammation.
Measure: Correlation between the extent of symptoms (dyspnoea-12 score and fatigue score) and multi-organ injury. Time: 3,6,12months.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports